Issues in noninferiority trials: the evidence in community-acquired pneumonia. - Wikidata - awgldk - TriplyDB

Issues in noninferiority trials: the evidence in community-acquired pneumonia.

Issues in noninferiority trials: the evidence in community-acquired pneumonia.

http://www.wikidata.org/entity/Q37170063

about

Evaluating interventions for Ebola: The need for randomized trials Recommended design features of future clinical trials of antibacterial agents for hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia.Recommendations for improving the design, conduct, and analysis of clinical trials in hospital-acquired pneumonia and ventilator-associated pneumonia.Through the looking glass: understanding non-inferiority.A simulation study evaluating bio-creep risk in serial non-inferiority clinical trials for preservation of effect.Some essential considerations in the design and conduct of non-inferiority trials Cethromycin versus clarithromycin for community-acquired pneumonia: comparative efficacy and safety outcomes from two double-blinded, randomized, parallel-group, multicenter, multinational noninferiority studies.Editorial commentary: Asking the right questions: morbidity, mortality, and measuring what's important in unbiased evaluations of antimicrobials.Excess deaths associated with tigecycline after approval based on noninferiority trials.Developing Outcomes Assessments as Endpoints for Registrational Clinical Trials of Antibacterial Drugs: 2015 Update From the Biomarkers Consortium of the Foundation for the National Institutes of Health.Noninferior Antibiotics: When Is "Not Bad" "Good Enough"?Noninferiority trials: clinical understandings and misunderstandings.Publication of noninferiority clinical trials: changes over a 20-year interval.Understanding the regulatory hurdles for antibacterial drug development in the post-Ketek world.Patient-Reported Outcome Assessments as Endpoints in Studies in Infectious Diseases.Noninferiority studies with multiple reference treatments.Non-inferiority clinical trials: Practical issues and current regulatory perspective Valomaciclovir versus valacyclovir for the treatment of acute herpes zoster in immunocompetent adults: a randomized, double-blind, active-controlled trial.Response to Spellberg and Brass.Adaptive Designs for Non-inferiority Trials with Multiple Experimental Treatments.Testing of non-inferiority and superiority for three-arm clinical studies with multiple experimental treatments.

P2860

Q28388002-3E41F21D-6907-4187-A392-CD31D83CD89C Q34165319-A6DE8C1A-2437-4A22-B576-60F66097B2F2 Q34470298-0E47B844-96E2-4551-8856-14F1C1593601 Q35042316-B6B83F55-C3C3-4674-9119-BE610C985522 Q35679667-23B7DC23-06DF-4E86-BA1A-2B84AD88081A Q35851943-B5F17FD4-49C7-40DC-AA6D-2E719A163966 Q35867451-CCE44A20-6DF7-4AD2-80EF-7A517BBB54BB Q36115620-7561098C-73B9-4EB1-8BF0-6FE6E3D2F8C1 Q36115632-16BC583F-73DA-48BC-9842-D09DF7EB44DC Q36543826-DA89230C-285B-44F3-999A-7E28AA81779B Q37057340-D8B58226-995E-4D93-A560-C0EB1849D729 Q37593414-8C5CE067-4175-44CF-987B-C867C39D269F Q37933403-D53260C3-A51E-45AC-8532-BC24C080A151 Q37970725-A18340C9-86B4-40B9-A4F5-7EDE8C7DA99D Q39534931-1856C8A3-63A9-4936-8056-43CA12128401 Q41189857-D6BA55A6-BAF6-488A-B906-0CF24CF4F076 Q41888310-614880B9-6282-4931-9CF2-9DCF1DDD5E22 Q43405240-035926A0-68DC-41AD-A0D0-0A6CB3E0BFF5 Q44031625-0F4C7038-4438-4BC3-89E7-D56936817F90 Q49338750-6AAFA6FB-7BED-4CAB-94EF-981820C8734A Q50581924-29319997-2D72-49A3-845E-8C77D04FE019

P2860

Issues in noninferiority trials: the evidence in community-acquired pneumonia.

http://www.wikidata.org/entity/Q37170063

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on December 2008

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Issues in noninferiority trials: the evidence in community-acquired pneumonia.

@en

Issues in noninferiority trials: the evidence in community-acquired pneumonia.

@nl

type

label

Issues in noninferiority trials: the evidence in community-acquired pneumonia.

@en

Issues in noninferiority trials: the evidence in community-acquired pneumonia.

@nl

prefLabel

Issues in noninferiority trials: the evidence in community-acquired pneumonia.

@en

Issues in noninferiority trials: the evidence in community-acquired pneumonia.

@nl

P1433

Q37170063-F447F1BA-9EA2-4021-8940-8EBDA2D81EE1

P1476

Q37170063-E3972DA5-BDAF-43C7-A88D-88B5D7B91E24

P2093

Q37170063-2A005C8B-DAAA-432A-8422-0F97DB3548CB

Q37170063-6AB3382B-870C-486F-825F-131F8DD86041

P2860

Q37170063-0203AF0E-BC8A-4F14-B409-BEB5545453F5

Q37170063-2A3F7DAB-944D-44D5-AADC-63ED730D2402

Q37170063-44982898-D974-4E09-B4B9-4AB7A8596D54

Q37170063-4FFE8346-B56E-483B-A115-E7E38FD1261E

Q37170063-6048655A-090A-4812-A914-C9981BE63E95

Q37170063-68EC634D-1D7B-4B9B-A65A-2920529153D3

Q37170063-6A0D6EE0-7286-441D-AA37-AB340D6D030B

Q37170063-7BD215A7-EF8D-4C05-9212-C27DF883EDFE

Q37170063-7E710687-10F3-42C8-AE61-0AFD0684212C

Q37170063-8CF387A6-9E48-451C-826F-3729EA3C6F9D

P304

Q37170063-F748E42F-F925-4750-91FE-749038C08568

P31

Q37170063-BC0BCC21-00DB-4F39-8CAB-2ACEE619BD2A

P356

Q37170063-3E92099E-D0BE-489D-B954-B4C26C01A5C4

P407

Q37170063-ED23A4EA-B627-4FE3-8221-E579A698316A

P478

Q37170063-6C795892-7BD7-4FA4-866E-7550BBF0809C

P577

Q37170063-C45FC6E2-C4B3-47DA-86FA-6ED927232156

P5875

Q37170063-FDB94BE0-C574-4DA5-8838-0A736FFDA0FD

P698

Q37170063-3BC7AB86-6A27-411A-8E2A-16439ACF7A60

P921

Q37170063-8D9D5838-49C7-451C-92E0-F34E997A0F3D

P932

Q37170063-3CC2E23A-EB2B-47ED-8F57-E799CF486090

P356

P1433

Clinical Infectious Diseases

P1476

Issues in noninferiority trials: the evidence in community-acquired pneumonia.

@en

P2093

John H Powers

http://www.w3.org/2001/XMLSchema#string

Thomas R Fleming

http://www.w3.org/2001/XMLSchema#string

P2860

Selective Publication of Antidepressant Trials and Its Influence on Apparent Efficacy

Noninferiority trials

Empirical evidence of bias in treatment effect estimates in controlled trials with different interventions and outcomes: meta-epidemiological study

Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials

A prediction rule to identify low-risk patients with community-acquired pneumonia

Empirical atypical coverage for inpatients with community-acquired pneumonia: systematic review of randomized controlled trials.

Outcomes in lower respiratory tract infections and the impact of antimicrobial drug resistance.

Effectiveness of beta lactam antibiotics compared with antibiotics active against atypical pathogens in non-severe community acquired pneumonia: meta-analysis.

The community-acquired pneumonia symptom questionnaire: a new, patient-based outcome measure to evaluate symptoms in patients with community-acquired pneumonia.

THE TREATMENT OF PNEUMOCOCCAL PNEUMONIA WITH DAGENAN (M. & B. 693).

P304

S108-20

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1086/591390

http://www.w3.org/2001/XMLSchema#string

P407

P478

47 Suppl 3

http://www.w3.org/2001/XMLSchema#string

P577

2008-12-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

23453507

http://www.w3.org/2001/XMLSchema#string

P698

18986275

http://www.w3.org/2001/XMLSchema#string

P921

P932

2673530

http://www.w3.org/2001/XMLSchema#string